Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rusfertide Extension Study in Polycythemia Vera
NCT06033586Phase 3Active, not recruiting
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Jan 2024
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of rusfertide in polycythemia vera (PV), sponsored by Protagonist Therapeutics, Inc.. Started Jan 2024; status: active, not recruiting.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06033586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033586.